Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 17/04/2026 BST			5-day change	1st Jan Change
927.03 ^USD	+2.55%		-1.32%	-13.74%

04-19	Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says	RE
04-19	Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion - WSJ	RE

Analyst Reco.

04-10	Rothschild & Co Redburn Adjusts Price Target on Eli Lilly to $880 From $875, Maintains Neutral Rating	MT
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-02	Eli Lilly's Foundayo Seen as Preferred Obesity Pill on Ease of Use, BofA Says	MT
04-02	BofA Securities Raises Price Target on Eli Lilly to $1,294 From $1,293, Maintains Buy Rating	MT
03-31	Analyst recommendations: Berkshire Hathaway, Blackrock, Eli Lilly, Unilever, Toyota…
03-30	Guggenheim Adjusts Price Target on Eli Lilly to $1,163 From $1,168, Maintains Buy Rating	MT
03-17	Health Care Down After HSBC Cuts Lilly Rating - Health Care Roundup	DJ
03-17	Analyst recommendations: Align Technology, Eli Lilly, Adobe, Salesforce…
03-17	HSBC Downgrades Eli Lilly to Reduce From Hold, Adjusts Price Target to $850 From $1,070	MT
03-12	Novo Nordisk Price Target Cut as Berenberg Expects Lower CagriSema Sales Amid Recent Clinical Data	MT
03-11	Wolfe Research Adjusts PT on Eli Lilly to $1,325 From $1,250, Maintains Outperform Rating	MT
03-09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
02-26	Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says	MT
02-26	Guggenheim Adjusts Price Target on Eli Lilly to $1,168 From $1,161, Maintains Buy Rating	MT
02-25	Eli Lilly Set to Benefit From Obesity Franchise Dominance, RBC Says	MT
02-25	RBC Initiates Eli Lilly at Outperform With $1,250 Price Target	MT
02-25	RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030	MT
02-23	Truist Securities Keeps Eli Lilly at Buy After Head-to-head Trial Results of Novo Nordisk's Obesity Drug	MT
02-23	Abivax Shows Jitters Despite Promising Updates on Obefazimod
02-23	Novo Nordisk Plummets After Setback for Obesity Drug – Shares Hit Lowest Level Since 2021	FW
02-23	Rothschild & Co Redburn Adjusts PT on Eli Lilly to $875 From $830, Maintains Neutral Rating	MT
02-19	Berenberg Ups Estimates, Price Target on Eli Lilly Amid 'Premium Growth, Premium Valuation'	MT
02-19	Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating	MT
02-18	Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial	RE
02-18	Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating	MT